Scientific Impact Paper No. 48: Management of Women with a Genetic Predisposition to Gynaecological Cancers

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Obstetrician & Gynaecologist

• Publication date

  2015-04-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1111/tog.12182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Hereditary gynecologic cancers

  2014cited by this paper
• Prophylactic Bilateral Salpingectomy as a Prevention Strategy in Women at High-Risk of Ovarian Cancer: A Mini-Review

  2014cited by this paper
• Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.

  2014cited by this paper
• Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts

  2013cited by this paper
• Genetic Testing by Cancer Site: Uterus

  2012cited by this paper
• Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer

  2012cited by this paper
• Genetic Testing by Cancer Site: Ovary

  2012cited by this paper
• Lifetime Cancer Risks in Individuals with Germline PTEN Mutations

  2012cited by this paper
• Outcome of risk‐reducing salpingo‐oophorectomy in BRCA carriers and women of unknown mutation status

  2011cited by this paper
• PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

  2011cited by this paper
• Germline mutations in RAD51D confer susceptibility to ovarian cancer

  2011influential reference
• Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

  2011cited by this paper
• Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

  2011cited by this paper
• Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

  2011cited by this paper
• Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan–Riley–Ruvalcaba syndrome clinical features

  2011cited by this paper
• Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

  2010cited by this paper
• Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

  2010cited by this paper
• Moving Toward Personalized Medicine: Treatment-Focused Genetic Testing of Women Newly Diagnosed With Ovarian Cancer

  2010cited by this paper
• The inherited genetics of ovarian and endometrial cancer.

  2010cited by this paper
• Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.

  2010cited by this paper
• Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer

  2009cited by this paper
• Pathology of BRCA-Associated Ovarian Cancers, Including Occult Cancers

  2008cited by this paper
• Oophorectomy as a risk factor for coronary heart disease.

  2008cited by this paper
• Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

  2008cited by this paper
• Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.

  2007cited by this paper
• Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome

  2007cited by this paper
• Ovarian cancer in younger vs older women: a population-based analysis

  2006cited by this paper
• Peutz-Jeghers syndrome and management recommendations.

  2006cited by this paper
• Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

  2006cited by this paper
• The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer.

  2006cited by this paper
• Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

  2006cited by this paper
• Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.

  2005cited by this paper
• Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

  2005cited by this paper
• Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome?

  2005cited by this paper
• Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.

  2005cited by this paper
• Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.

  2004cited by this paper
• Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

  2004cited by this paper
• Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.

  2004cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis.

  2003cited by this paper
• Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

  2002cited by this paper
• Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

  2002cited by this paper
• The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer.

  2001cited by this paper
• Distinct functions of BRCA1 and BRCA2 in double-strand break repair

  2001cited by this paper
• Cancer risk in mutation carriers of DNA‐mismatch‐repair genes

  1999cited by this paper
• New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

  1999cited by this paper
• Germ-line msh6 mutations in colorectal cancer families.

  1999cited by this paper
• BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.

  1998cited by this paper
• A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

  1998cited by this paper
• Ovarian cancer screening

  1997cited by this paper
• A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group.

  1996cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1996cited by this paper
• Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1995cited by this paper
• Mutation of a mutL homolog in hereditary colon cancer.

  1994cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.

  1993cited by this paper
• Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer.

  1993cited by this paper
• Hereditary Ovarian Cancer: A Clinicopathological Study

  1992cited by this paper
• Hereditary Colorectal Cancer

  1990cited by this paper
• A cancer family syndrome in twenty-four kindreds.

  1988cited by this paper

• Executive Summary of the Ovarian Cancer Evidence Review Conference

  2023cites this paper
• Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2

  2022cites this paper
• From proband to provider: is there an obligation to inform genetic relatives of actionable risks discovered through direct-to-consumer genetic testing?

  2020cites this paper
• Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants

  2019cites this paper
• Review Article: Sexuality and Risk-Reducing Salpingo-oophorectomy

  2017cites this paper
• Genetic testing in a gynaecological oncology care in developing countries—knowledge, attitudes and perception of Nepalese clinicians

  2016cites this paper
• Diagnosis of ovarian cancer

  2015cites this paper